Merck has completed patient enrolment for a pivotal Phase III clinical trial evaluating the efficacy of Erbitux (cetuximab) for the treatment of patients with advanced gastric cancer.
The trial will evaluate the efficacy of Erbitux in combination with cisplatin and capecitabine chemotherapies as a first line treatment for patients with advanced or metastatic gastric adenocarcinoma, including gastroesophageal junction adenocarcinoma.
The multicentre, open label, randomised and controlled study is being conducted at 185 centres across 25 countries including Latin America, Europe, Asia-Pacific and Japan, and has enrolled more than 870 patients.
The primary endpoint of the study will be progression-free survival.
Erbitux is a first-in-class and highly active IgG1 monoclonal antibody, which targets the epidermal growth factor receptor.
